
Mantle Cell Lymphoma
Latest News

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Latest Videos

CME Content
More News

Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.

The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.

The frontline combination of obinutuzumab and zanubrutinib demonstrated efficacy and safety in older patients with mantle cell lymphoma.

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.




















































